KNX 100
Alternative Names: KNX-100; SOC-1Latest Information Update: 25 Dec 2023
At a glance
- Originator University of Sydney
- Developer Kinoxis Therapeutics
- Class Appetite stimulants; Drug withdrawal therapies; Small molecules
- Mechanism of Action Oxytocin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Opioid-related disorders
- Preclinical Behavioural disorders
Most Recent Events
- 30 Sep 2023 Kinoxis Therapeutics completes a phase I trial in opioid-related disorders (In volunteers) in Australia (NCT04901078)
- 12 Apr 2023 Preclinical trials in Behavioural disorders in Australia (PO) (Kinoxis Therapeutics pipeline, April 2023)
- 23 Jun 2022 Phase-I clinical trials in Substance-related disorders in Australia (PO)